Prakash Hariprasath, Chakrabarti Arunaloke
Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India.
J Fungi (Basel). 2019 Mar 21;5(1):26. doi: 10.3390/jof5010026.
Mucormycosis is an angio-invasive fungal infection, associated with high morbidity and mortality. A change in the epidemiology of mucormycosis has been observed in recent years with the rise in incidence, new causative agents and susceptible population. The rise has been perceived globally, but it is very high in the Asian continent. Though diabetes mellitus overshadow all other risk factors in Asia, post-tuberculosis and chronic renal failure have emerged as new risk groups. The rhino-cerebral form of mucormycosis is most commonly seen in patients with diabetes mellitus, whereas, pulmonary mucormycosis in patients with haematological malignancy and transplant recipients. In immunocompetent hosts, cutaneous mucormycosis is commonly seen following trauma. The intriguing clinical entity, isolated renal mucormycosis in immunocompetent patients is only reported from China and India. A new clinical entity, indolent mucormycosis in nasal sinuses, is recently recognized. The causative agents of mucormycosis vary across different geographic locations. Though is the most common agent isolated worldwide, is predominant in Asia and species in Europe. The new causative agents, , , and are reported from Asia. In conclusion, with the change in epidemiology of mucormycosis country-wise studies are warranted to estimate disease burden in different risk groups, analyse the clinical disease pattern and identify the new etiological agents.
毛霉病是一种血管侵袭性真菌感染,与高发病率和死亡率相关。近年来,随着发病率上升、新的致病病原体和易感人群的出现,毛霉病的流行病学发生了变化。这种上升在全球范围内都有体现,但在亚洲大陆尤为显著。尽管在亚洲糖尿病掩盖了所有其他风险因素,但肺结核后和慢性肾衰竭已成为新的风险群体。鼻脑型毛霉病最常见于糖尿病患者,而肺部毛霉病则常见于血液系统恶性肿瘤患者和移植受者。在免疫功能正常的宿主中,皮肤毛霉病常见于创伤后。免疫功能正常患者中孤立性肾毛霉病这种有趣的临床实体仅在中国和印度有报道。一种新的临床实体,即鼻窦惰性毛霉病,最近被认识到。毛霉病的致病病原体在不同地理位置有所不同。尽管 是全球分离出的最常见病原体,但 在亚洲占主导,在欧洲则以 种为主。新的致病病原体, 、 、 和 在亚洲有报道。总之,随着毛霉病流行病学的变化,有必要进行国别研究以估计不同风险群体的疾病负担,分析临床疾病模式并确定新的病原体。 (原文中部分病原体名称未给出具体内容,用 等代替)